CO-DIAGNOSTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.35 USD | +3.85% |
|
+8.00% | +1.50% |
| Jul. 02 | Co-Diagnostics Expands Vector Control Customer Base | MT |
| Jul. 02 | Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers Across 15 U.S. States | CI |
Financials (USD)
| Sales 2024 * | 1.59M | Sales 2025 * | 1.5M | Capitalization | 42.23M |
|---|---|---|---|---|---|
| Net income 2024 * | -41M | Net income 2025 * | -42M | EV / Sales 2024 * | 26.5 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 28.2 x |
| P/E ratio 2024 * |
-1.02
x | P/E ratio 2025 * |
-1.17
x | Employees | 155 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on Co-Diagnostics, Inc.
More recommendations
More press releases
| 1 day | +3.85% | ||
| 1 week | +8.00% | ||
| Current month | +8.00% | ||
| 1 month | -1.46% | ||
| 3 months | +12.50% | ||
| 6 months | -3.57% | ||
| Current year | +1.50% |
1 week
1.21
1.39
1 month
1.201.73
Current year
1.001.73
1 year
0.981.89
3 years
0.9811.82
5 years
0.8530.99
10 years
0.6930.99
| Managers | Title | Age | Since |
|---|---|---|---|
Dwight Egan
CEO | Chief Executive Officer | 70 | 13-04-17 |
Brian Brown
DFI | Director of Finance/CFO | 48 | 21-02-21 |
Andrew Benson
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Reed L. Benson
LAW | General Counsel | 77 | 14-10-31 |
Richard Serbin
BRD | Director/Board Member | 79 | 17-04-30 |
Dwight Egan
CEO | Chief Executive Officer | 70 | 13-04-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.37% | 28 M€ | -0.43% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-12 | 1.35 | +3.85% | 40,102 |
| 24-07-11 | 1.3 | -5.11% | 136,644 |
| 24-07-10 | 1.37 | +11.38% | 133,564 |
| 24-07-09 | 1.23 | -0.81% | 24,835 |
| 24-07-08 | 1.24 | -0.80% | 42,858 |
Delayed Quote Nasdaq, July 12, 2024 at 04:00 pm EDT
More quotes
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Companyâs technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the userâs mobile device.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.35
USD
Average target price
2
USD
Spread / Average Target
+48.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.50% | 42.23M | |
| -27.91% | 16.33B | |
| -56.07% | 2.17B | |
| +19.09% | 1.88B | |
| -12.63% | 1.45B | |
| +29.99% | 1.32B | |
| +8.32% | 853M | |
| -30.60% | 799M | |
| -36.50% | 726M | |
| +29.48% | 622M |
- Stock Market
- Equities
- CODX Stock
